<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009670</url>
  </required_header>
  <id_info>
    <org_study_id>Inulin and SCFA production</org_study_id>
    <nct_id>NCT02009670</nct_id>
  </id_info>
  <brief_title>Inulin,SCFA Production and Metabolic Response</brief_title>
  <official_title>SCFA Production and Their Metabolic Effects After Inulin Ingestion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this placebo controlled, double-blind, randomized crossover study the investigators will
      investigate in overweight/obese healthy male volunteers whether inulin administration will
      increase intestinal SCFA production, thereby investigating whether this will lead to acute
      metabolic effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota is being increasingly recognized as an important factor in fat distribution,
      insulin sensitivity and glucose and lipid metabolism. Accordingly, the intestinal microbiota
      could play an important role in the development of obesity and type 2 diabetes mellitus. The
      role of gut-derived short-chain fatty acids (SCFA), the formation of which is enhanced by
      microbial fermentation of fibre, is still controversial. At the present time, our
      understanding of the effects of SCFA on human metabolism (in gut or systemically) is still
      limited. The investigators hypothesize that the ingested prebiotic inulin is fermented into
      SCFA and these SCFA have metabolic effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat oxidation, energy expenditure</measure>
    <time_frame>1 study day for each administration</time_frame>
    <description>Fat oxidation and energy expenditure are measured after inulin ingestion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormones that influence substrate and energy metabolism</measure>
    <time_frame>1 study day for each administration</time_frame>
    <description>Insulin, GLP-1, PYY will be measured in plasma after inulin ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating metabolites</measure>
    <time_frame>1 study day for each administration</time_frame>
    <description>Glucose, FFA, TG will be measured in plasma after inulin ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite VAS scoring</measure>
    <time_frame>1 study day for each administration</time_frame>
    <description>Visual Analogue Scale for hunger and appetite are completed after inulin ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCFAs</measure>
    <time_frame>1 study day for each administration</time_frame>
    <description>SCFA content (acetate, butyrate and propionate, unlabeled and 13C-labeled) are measured after inulin ingestion in plasma, faeces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath sampling 13CO2</measure>
    <time_frame>1 study day for each administration</time_frame>
    <description>In breath samples 13CO2 will be measured after inulin ingestion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>13C inulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13C inulin combined with an inulin load are administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo is administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>13C inulin</intervention_name>
    <description>Oral 13C inulin</description>
    <arm_group_label>13C inulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight, obese men

        Exclusion Criteria:

          -  athletes

          -  diabetes mellitus
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHC Dejong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <zip>6229ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

